Health Dictionary Find a Doctor

Roseola

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Synonyms and keywords: Roseola infantum, exanthem subitum, sixth disease, 3 day rash, pseudorubella, exanthem criticum

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

Roseola is a disease of infants. It is characterized by an abrupt rise in body temperature to as high as 40°C (104°F) followed by a rapid drop to normal within the next 2–4 days which coincides with the appearance of an erythematous maculopapular skin rash that persists for 1–3 days. It is typically a benign disease which resolves without sequelae. Roseola disease is caused by Human herpes virus 6 (HHV6). HHV-6A and HHV-6B are two distinct species of HHV-6.

Historical perspective

For the first time, Zahorsky of St. Louis in 1910 described a febrile exanthem occurring in infants which he termed roseola. Human herpes virus 6 was first identified in 1986.

Classification

There is no established classification system for roseola.

Pathophysiology

Roseola has two phases, the febrile and the rash (maculopapular) phase. During the first phase, HHV6 replicates in salivary glands and is secreted as primary source of infection. After complete resolution of the febrile phase, due to the latency of the virus in the lymphocytes and monocytes, the rash phase begins. A more serious form of HHV 6 is seen in older children, immunocompromised adults and organ transplant patients.

Causes

Roseola is caused by Human herpes virus 6, a member of the Herpesvirales order, Herpesviridae family, Betaherpesvirinae subfamily, and Roseolovirus genus. Herpesviruses have a unique four-layered structure: a core containing the large, double-stranded DNA genome is enclosed by an icosapentahedral capsid which is composed of capsomers. The capsid is surrounded by an amorphous protein coat called the tegument. It is encased in a glycoprotein-bearing lipid bilayer envelope.

Differential diagnosis

Roseola must be differentiated from other diseases that cause fever and rash, such as Rubella (german measles), Rubeola (measles), hand foot and mouth disease caused by coxsackie virus, erythema infectiosum caused by parvovirus B19, scarlet fever and even drug allergy.

Epidemiology and demographics

There is no accurate data for the prevalence or incidence of roseola. This is because the disease is a self limiting disease and it is under reported in most cases. Roseola is an illness of young children, with a peak prevalence between 7 and 13 months. Ninety percent of cases occur in children younger than two years. Roseola occurs equally in boys and girls. It occurs throughout the year, although outbreaks may occur in groups according to season 

Risk factors

The common risk factors in the development of roseola includes infancy (younger 2 years), immunosuppression, and organ transplantation.

Screening

According to the USPSTF, there is insufficient evidence to recommend routine screening for roseola.

Natural history complications and prognosis

The symptoms of roseola usually starts in the first 2 years of life of an infant. If roseola, left untreated, it will resolve by itself. In rare cases, febrile seizures, encephalitis, aseptic meningitis, thrombocytopenic purpura, bone marrow failure and pneumonitis. The overall prognosis of roseola is very good.

Diagnosis

History and Symptoms

The hallmark of roseola is a non pruritic macular or maculopapular rash. A positive history of a high fever of 40ºC (104ºF) that lasts for 3 to 5 days.

Physical Examination

Physical examination findings in a patient with roseola will depend on the presenting phase (febrile or rash). Vital signs are affected in the febrile phase and stabilize in the rash phase. Conversely, in the rash phase, vital signs become normal while skin appearance is affected.

Laboratory Findings

The diagnosis of roseola is made clinically. However, in atypical cases, the diagnosis can be made by both serologic and direct detection of HHV6 virus in the saliva of the patient. Expected results of diagnostic studies include antigen detection, PCR, and immunofluorescence.

Electrocardiogram

There are no electrocardiogram findings associated with roseola.

Chest X Ray

There are no chest x ray findings associated with roseola.

MRI

There are no MRI findings associated with roseola.

Echocardiography or ultrasound

There are no echocardiography or ultrasound findings associated with roseola.

Other imaging findings

There are no other imaging findings associated with roseola.

Other diagnostic studies

There are no other diagnostic studies associated with roseola.

Treatment

Medical therapy

There is no treatment for roseola; it is a self limiting disease that resolves on its own without any medical intervention but antipyretics can be used as a supportive therapy in cases of high fever.[1]

Surgery

Surgical intervention is not recommended for the management of roseola.

Primary prevention

There is no established method of prevention of roseola. However, standard sanitary procedures such as hand washing can help prevent the spread of the HHV 6 virus.

Secondary prevention

There are no secondary preventive measures available for roseola.

References

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

For the first time, Zahorsky of St. Louis in 1910 described a febrile exanthem occurring in infants which he termed roseola. Human herpes virus 6 was first identified in 1986.

Historical Perspective

  • For the first time, Zahorsky of St. Louis in 1910 described a febrile exanthem occurring in infants which he termed roseola.
  • In 1986, Human herpes virus 6 (HHV6), the main causative agent of roseola disease was first isolated from patients who were diagnosed with HIV AIDS or a lymphoproliferative disorder from the peripheral blood leukocytes. [1]
  • The two different variants of HHV 6 discovered by Frenkel, Ablashi and Aubin are variant A and Variant B HHV 6 strains.[2][3][4]
  • HHV 6A has been found to be more associated with the development of roseola.

References

  1. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M; et al. (1986). “Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders”. Science. 234 (4776): 596–601. PMID 2876520.
  2. Schirmer EC, Wyatt LS, Yamanishi K, Rodriguez WJ, Frenkel N (1991). “Differentiation between two distinct classes of viruses now classified as human herpesvirus 6”. Proc Natl Acad Sci U S A. 88 (13): 5922–6. PMC 51990. PMID 1648234.
  3. Ablashi DV, Balachandran N, Josephs SF, Hung CL, Krueger GR, Kramarsky B; et al. (1991). “Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates”. Virology. 184 (2): 545–52. PMID 1653487.
  4. Aubin JT, Collandre H, Candotti D, Ingrand D, Rouzioux C, Burgard M; et al. (1991). “Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction”. J Clin Microbiol. 29 (2): 367–72. PMC 269769. PMID 1848868.
Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

There is no established classification system for roseola.

Classification

There is no established classification system for roseola.

References

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

Roseola has two phases, the febrile and the rash (maculopapular) phase. During the first phase, HHV6 replicates in salivary glands and is secreted as primary source of infection. After completes resolution of the febrile phase, due to the latency of the virus in the lymphocytes and monocytes, the rash phase begins.

Pathophysiology

Roseola has two phases:

  1. The febrile phase
  2. The rash phase

Transmission of infection

The febrile phase

The rash phase

Pathogenesis

Genetics

Chromosomal integration of HHV-6A and HHV-6B is responsible for transmission of infection from the parents to the newborn and is observed in 1% of the population.

Associated conditions

A more serious form of HHV 6 is seen in older children, immunocompromised adults and organ transplant patients.

Gross pathology

There are no gross pathologic findings associated with roseola.

Microscopic pathology

There are no microscopic findings associated with roseola.

References

  1. 1.0 1.1 JURETIC M (1963). “Exanthema subitum a review of 243 cases”. Helv Paediatr Acta. 18: 80–95. PMID 13958107.
  2. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T; et al. (1994). “Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum)”. Pediatrics. 93 (1): 104–8. PMID 8265302.
  3. Stoeckle MY (2000). “The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease”. Annu Rev Med. 51: 423–30. doi:10.1146/annurev.med.51.1.423. PMID 10774474.
  4. 4.0 4.1 BERENBERG W, WRIGHT S, JANEWAY CA (1949). “Roseola infantum (exanthem subitum)”. N Engl J Med. 241 (7): 253–9. doi:10.1056/NEJM194908182410701. PMID 18138680.
Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

Roseola may be caused by either Human herpes virus 6A, 6B and 7 (HHV6A, HHV6B and HHV 7). The most common cause is HHV6B. Other causes include enteroviruses (Coxsackie A and B, echoviruses), adenoviruses and parainfluenza viruses.

Causes

References

  1. Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K (1994). “Human herpesvirus 7: another causal agent for roseola (exanthem subitum)”. J Pediatr. 125 (1): 1–5. PMID 8021757.
  2. Agut H, Bonnafous P, Gautheret-Dejean A (2017). “Update on infections with human herpesviruses 6A, 6B, and 7”. Med Mal Infect. 47 (2): 83–91. doi:10.1016/j.medmal.2016.09.004. PMID 27773488.
Differentiating Any Disease from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

Roseola must be differentiated from other diseases that cause fever and rash, such as Rubella (german measles), Rubeola (measles), hand foot and mouth disease caused by coxakie virus, erythema infectiosum caused by parvovirus B19, scarlet fever and even drug allergy.

Differential diagnosis

Roseola, also known as Exanthem subitum must be differentiated from all other childhood diseases that cause rash, and fever. The following table summarizes the differential diagnosis for roseola.[1][2][3][4][5][6][7][8]

Differential Diagnosis of fever and rash.
Disease Cause Typical Age Prodrome Fever Duration of the rash (days) Workup Treatment
Roseola Infantum (exanthem subitum) Human herpes virus type 6 6 months to 2 years None High 1-2; it follows defervescence Discrete erythematous macules, rarely involves face, begins as fever ends Lymphadenopathy, irritability
Measles Paramyxovirus
Measles virus
1 to 20 years 2-4 days of cough, conjunctivitis, and coryza High 5 – 6 Erythematous, irregular size, maculopapular; starts on temples and behind ears; progresses down from face; fades to brownish Koplik’s spots: C blue-white papules (salt grains) on bright red mucosa opposite premolar teeth
Rubella Togavirus 7 months to 29 years 0 – 4 days; mild malaise, fever; absent in children Low grade 1 – 3 Discrete, rose-pink, diffuse, maculopapular; progresses downward from face, may change quickly Arthralgia (usually in adults), tender posterior cervical and suboccipital lymphadenopathy, malaise, petechiae on soft palate
Erythema Infectiosum (Fifth Disease) Human parvovirus type B19 5 – 10 years None, usually in children, may occur in adults None to low-grade 2 – 4 Starts as “slapped cheek”, maculopapular; progresses to reticular (lacy) pattern; can recur with environmental changes such as sunlight exposure Arthralgia/arthritis in adults, adenopathy
Infectious Mononucleosis Epstein-Barr Virus 10 – 30 years 2 – 5 days of malaise and fatigue Low to high 2 – 7 Trunk and proximal extremities. Rash common if Ampicillin given Pharyngitis, lymphadenopathy, splenomegaly, malaise
Kawasaki disease Unknown < 5 years 3 days of abrupt fever High; fever of 5 days is a diagnostic criteria 5 – 7 Erythematous, morbilliform, maculopapular or scarlatiniform, central distribution; erythematous, indurated palms and soles Acute: dry, fissured and injected lips, strawberry tongue; irritability; cervical lymphadenopathy; conjunctival injection; peripheral edema; Subacute: finger-tip desquamation; Complications: arthritis, carditis
Scarlet Fever ß-hemolytic streptococci > 2 years 0 – 6 day, marked Low to high 2 – 7 Scarlet “sunburn” with punctate papules “sandpaper”, circumoral pallor, increased intensity in skin folds, blanches stars face/head, upper trunk and progresses downward Sore throat, exudative tonsillitis, vomiting, abdominal pain, lmphadenopathy, white then red strawberry tongue
Enterovirus Echovirus
Coxsackie virus
Mainly childhood 0 – 1 day fever and myalias Low to high 1 – 5 Fine, pink, always affects face; variant is Boston exanthem (large ~ 1 cm, discrete maculopapules) Sore throat, headache, malaise, no lymphadenopathy, gastroenteritis
Dengue Fever Flavivirus
Dengue virus types 1 – 4
None High 1 – 5 Generalized maculopapular rash after defervescence; spares palms and soles Headache, myalgia, abdominal pain, pharyngitis, vomiting
Drug induced rash Many Any Possible due to underlying illness Possible Varies Typically diffuse but may be concentrated in diaper area, typically no progression, erythema multiform rash can progress over a few days Possibly due to underlying illness or complications
Pharyngoconjunctival Fever Adenovirus types 2, 3, 4, 7, 7a < 5 years Low to high 3 – 5 Starts on face and spreads down to trunk and extremities Sore throat, conjunctivitis, headache, anorexia

Table adapted from CDC Pinkbook.[9]

References

  1. JURETIC M (1963). “Exanthema subitum a review of 243 cases”. Helv Paediatr Acta. 18: 80–95. PMID 13958107.
  2. Robbins, Frederick C. (1962). “Measles: Clinical Features”. American Journal of Diseases of Children. 103 (3): 266. doi:10.1001/archpedi.1962.02080020278018. ISSN 0002-922X.
  3. Thompson, Amy E. (2015). “Recognizing Measles”. JAMA. 313 (15): 1584. doi:10.1001/jama.2015.1889. ISSN 0098-7484.
  4. Kaplan, Leonard J. (1992). “Severe Measles in Immunocompromised Patients”. JAMA: The Journal of the American Medical Association. 267 (9): 1237. doi:10.1001/jama.1992.03480090085032. ISSN 0098-7484.
  5. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F; et al. (1995). “Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody”. J Clin Microbiol. 33 (4): 811–5. PMC 228046. PMID 7790442.
  6. Papania, Mark J.; Wallace, Gregory S.; Rota, Paul A.; Icenogle, Joseph P.; Fiebelkorn, Amy Parker; Armstrong, Gregory L.; Reef, Susan E.; Redd, Susan B.; Abernathy, Emily S.; Barskey, Albert E.; Hao, Lijuan; McLean, Huong Q.; Rota, Jennifer S.; Bellini, William J.; Seward, Jane F. (2014). “Elimination of Endemic Measles, Rubella, and Congenital Rubella Syndrome From the Western Hemisphere”. JAMA Pediatrics. 168 (2): 148. doi:10.1001/jamapediatrics.2013.4342. ISSN 2168-6203.
  7. Jayaprakash B, Sudha V, Shashikiran U (2006). “Atypical presentation of adult rubella”. Med J Malaysia. 61 (2): 242–4. PMID 16898322.
  8. Dimech, W.; Panagiotopoulos, L.; Marler, J.; Laven, N.; Leeson, S.; Dax, E. M. (2005). “Evaluation of Three Immunoassays Used for Detection of Anti-Rubella Virus Immunoglobulin M Antibodies”. Clinical and Vaccine Immunology. 12 (9): 1104–1108. doi:10.1128/CDLI.12.9.1104-1108.2005. ISSN 1556-6811.
  9. “Epidemiology and Prevention of Vaccine-Preventable Diseases”.
Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

There is no accurate data for the prevalence or incidence of roseola. This is because the disease is a self limiting disease and it is under reported in most cases. Roseola is an illness of young children, with a peak prevalence between 7 and 13 months. Ninety percent of cases occur in children younger than two years. Roseola occurs equally in boys and girls. It occurs throughout the year, although outbreaks may occur in groups according to season .

Epidemiology and demographics

Prevalence

  • There is no accurate data for the prevalence or incidence of roseola.
  • More than 90% of adult populations in developed countries are seropositive for HHV 6.

Age

Roseola commonly affects young children between the ages of 7 and 13 months.[1]

Gender

  • Males and females are affected equally by roseola.[2]

Race

  • There is no racial predilection for roseola.

Developed countries

  • HHV6 infection is nearly universal accounting for 10-45% of febrile illness in infants.

Developing countries

  • There is a strong association of HHV 6A in Zambian children when compared to rest of the world.

References

  1. JURETIC M (1963). “Exanthema subitum a review of 243 cases”. Helv Paediatr Acta. 18: 80–95. PMID 13958107.
  2. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T; et al. (1994). “Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum)”. Pediatrics. 93 (1): 104–8. PMID 8265302.
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

The common risk factors in the development of roseola includes infancy (younger 2 years), immunosuppression, and organ transplantation.

Risk factors

Risk factors predisposing to roseola infection include:

References

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

According to the USPSTF, there is insufficient evidence to recommend routine screening for roseola.

Screening

According to the USPSTF, there is insufficient evidence to recommend routine screening for roseola.

References

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

The symptoms of roseola usually starts in the first 2 years of life of an infant. If roseola is left untreated, it will resolve by itself. In rare cases, febrile seizures, encephalitis, aseptic meningitis, thrombocytopenic purpura, bone marrow failure and pneumonitis. The overall prognosis of roseola is very good.

Natural history, complications and prognosis

Natural history

  • The symptoms of roseola usually start in the first 2 years of life of an infant. It starts as a high fever 40ºC (104ºF) which lasts for 3 to 5 days, as the fever abates, the child develops a non pruritic blanching papular or maculopapular rash that starts on the neck and progresses downward.[1]
  • Roseola is a self limiting disease; if left untreated, it resolves without any sequelae.

Complications

Roseola is usually benign and self limited. However patients with HIV or immunosuppressed patients may experience reactivation of the virus and signs and symptoms such as:[1]

Prognosis

The prognosis of roseola is good even without treatment. It is a self limiting disease, most children recover without any sequelae.[2][3]


References

  1. 1.0 1.1 JURETIC M (1963). “Exanthema subitum a review of 243 cases”. Helv Paediatr Acta. 18: 80–95. PMID 13958107.
  2. Fölster-Holst R, Kreth HW (2009). “Viral exanthems in childhood–infectious (direct) exanthems. Part 2: Other viral exanthems”. J Dtsch Dermatol Ges. 7 (5): 414–9. doi:10.1111/j.1610-0387.2008.06869.x. PMID 18808380.
  3. Thomas, Emy Aby; John, Mary; Bhatia, Anuradha (2007). “Cutaneous manifestations of dengue viral infection in Punjab (north India)”. International Journal of Dermatology. 46 (7): 715–719. doi:10.1111/j.1365-4632.2007.03298.x. ISSN 0011-9059.
Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH